3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Neoplasms
10
Breast Neoplasms
9
Prostatic Neoplasms
7
Multiple Myeloma
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Leukemia, Myeloid, Acute
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Neoplasms, Plasma Cell
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms by Site
2
Mycoses
2
Medication Adherence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Leukemia
2
Carcinoma, Transitional Cell
2
COVID-19
2
Adenocarcinoma
2
Uveal Melanoma
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Interventions
Cyclophosphamide
17
blinatumomab
16
fludarabine
13
Vincristine
11
Cytarabine
10
tisagenlecleucel
8
pegaspargase
8
nilotinib
8
Methotrexate
8
Inotuzumab Ozogamicin
8
Clofarabine
8
venetoclax
7
Dexamethasone
7
asparaginase erwinia chrysanthemi recombinant
6
Dasatinib
6
Azacitidine
5
AP 1903 reagent
5
aflibercept
4
Mercaptopurine
4
Imatinib Mesylate
4
Filgrastim
4
Etoposide
4
Drug Therapy
4
Daunorubicin
4
ponatinib
3
Sensitivity and Specificity
3
Mitoxantrone
3
Immunotherapy, Adoptive
3
Granulocyte Colony-Stimulating Factor
3
CPX-351
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Standard of Care
×
Clear all
NCT05316701
2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3
Active not recruiting
187 enrolled
15 charts